PPT-LPV-RTV + 3TC vs. LPV-RTV + 2 NRTIs in

Virologically Suppressed OLE Trial LPVRTV 3TC vs LPV RTV 2 NRTIs in Virologically Suppressed OLE Study Design Source Arribas JR et al Lancet Infect Dis 201515 78592. monotherapy. MONOI. MONET. PROTEA. DRV600. Design. Objective. Non inferiority in the proportion of patients with HIV-1 RNA < 50 c/. mL. at W48 (ITT analysis, missing/discontinuation/switch= failure, snapshot algorithm. Learning Objectives. Understand when to switch to a second-line regimen. Know preferred second-line regimens for adults (including pregnant and breastfeeding women), adolescents, and children. Describe common drug resistance mutations and how they influence choosing a second-line regimen. 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. Martina Penazzato MD, PhD. Paediatric lead, HIV Department. World Health Organization, Geneva. Background. 1.8 million children were estimated to live with HIV in 2017. In 2017, only 51 % of HIV-exposed infants received EID (by 2mo). Evidence-Based Approaches. Simply Speaking. ®. HIV “Essentials for Optimal Care of HIV Patients: Evidence-Based Approaches” is. Copyrighted 2018 by Practice Point Communications, unless otherwise noted.  All rights reserved.. ART in Women and Contraception: InSTIs , Comorbid Conditions, and Other Current Issues Sharon A. Nachman , MD Professor of Pediatrics Associate Dean for Research SUNY Stony Brook University Stony Brook, New York Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Financial Relationships With Commercial Entities. Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. 2 NRTIs in Treatment-Experienced. M97-765 Trial. Lopinavir. -RTV + . Nevirapine. + 2 NRTIs in Treatment-Experienced . M97-765: . Study Design. Source. : . Benson CA, et al. . J . Infect. . Dis. . 2002;185:599-607.. Professor Francois Venter. Ezintsha, University of the Witwatersrand, Johannesburg, South Africa. Thanks to: The Ezintsha team, HE²RO, Sydney Rosen, Anna . Grismrud. , Phumla . Sinxabi. , Andrew Hill, Gary Maartens, Mohammed Ali, Mark Siedner, Elvin Geng, Aaloke Mody, Jeff Wing, Vince Marconi, Yogan Pillay, Liesel Page-Shipp, Thato Chidarikire. FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. E Duke. https://www.hiv.uw.edu/page/treatment/drugs. David . Spach’s. National HIV Curriculum. HIV . Virion. ssRNA. Reverse Transcriptase. Integrase. HIV . Virion. CD4 T Lymphocyte. Human CD4+ T cell. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs.